These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27663402)

  • 1. Prognostic and Predictive Value of KRAS Mutation in NSCLC.
    Yamamoto S; Washington L; Komiya T
    J Thorac Oncol; 2016 Oct; 11(10):e128-9. PubMed ID: 27663402
    [No Abstract]   [Full Text] [Related]  

  • 2. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
    Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
    Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.
    Tímár J
    Curr Opin Oncol; 2014 Mar; 26(2):138-44. PubMed ID: 24463346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
    Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
    Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value].
    Planchard D; Loriot Y; Besse B
    Bull Cancer; 2009 Dec; 96 Suppl():S57-68. PubMed ID: 20034871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
    Shepherd FA; Lacas B; Le Teuff G; Hainaut P; Jänne PA; Pignon JP; Le Chevalier T; Seymour L; Douillard JY; Graziano S; Brambilla E; Pirker R; Filipits M; Kratzke R; Soria JC; Tsao MS;
    J Clin Oncol; 2017 Jun; 35(18):2018-2027. PubMed ID: 28453411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
    Svaton M; Fiala O; Pesek M; Bortlicek Z; Minarik M; Benesova L; Topolcan O
    Anticancer Res; 2016 Mar; 36(3):1077-82. PubMed ID: 26977001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation: should we test for it, and does it matter?
    Roberts PJ; Stinchcombe TE
    J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
    Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
    Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
    Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
    Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.
    Matikas A; Mistriotis D; Georgoulias V; Kotsakis A
    Crit Rev Oncol Hematol; 2017 Feb; 110():1-12. PubMed ID: 28109399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
    Martin P; Leighl NB; Tsao MS; Shepherd FA
    J Thorac Oncol; 2013 May; 8(5):530-42. PubMed ID: 23524403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.
    Chakrabarti G
    Radiat Oncol; 2015 Jul; 10():145. PubMed ID: 26173780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.